Roy Shipra, Kothari Nikhil, Sharma Ankur, Goyal Shilpa, Sankanagoudar Shrimanjunath, Bhatia Pradeep Kumar, Sharma Praveen
Department of Anesthesiology and Critical Care, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Department of Trauma and Emergency (Anesthesiology and Critical Care), All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Indian J Crit Care Med. 2023 Apr;27(4):289-293. doi: 10.5005/jp-journals-10071-24439.
Early diagnosis of sepsis is crucial to institute appropriate therapy and then to avert a possible negative outcome. We planned this study to evaluate the diagnostic value of presepsin, its sensitivity and specificity for diagnosing sepsis in critically ill patients, and its ability to prognosticate the outcome of sepsis.
In this prospective observational study, adult patients admitted to the intensive care unit (ICU) at our institute were screened, and those with features suggestive of sepsis were recruited into the study. Procalcitonin (PCT) and presepsin were assessed on the day of admission and day 7 of the ICU stay, apart from routine investigations. Patients were followed for outcome in terms of mortality till 28 days.
The study comprised 82 patients who satisfied the inclusion criteria. Presepsin sensitivity for sepsis diagnosis was determined to be 78%, while that of PCT was determined to be 69%. This gave a combined sensitivity of presepsin and PCT of 93% when used in parallel for the diagnosis of sepsis.
A combination of PCT and presepsin provides higher sensitivity and can be used to screen for sepsis in the ICU.
Roy S, Kothari N, Sharma A, Goyal S, Sankanagoudar S, Bhatia PK, Comparison of Diagnostic Accuracy of Presepsin and Procalcitonin for Sepsis in Critically Ill Patients: A Prospective Observational Study. Indian J Crit Care Med 2023;27(4):289-293.
脓毒症的早期诊断对于实施恰当治疗从而避免可能的不良后果至关重要。我们开展本研究以评估可溶性髓系细胞触发受体-1（presepsin）的诊断价值、其诊断重症患者脓毒症的敏感性和特异性，以及其对脓毒症预后的预测能力。
在这项前瞻性观察性研究中，对我院重症监护病房（ICU）收治的成年患者进行筛查，将具有脓毒症特征的患者纳入研究。除常规检查外，在入院当天和入住ICU第7天评估降钙素原（PCT）和可溶性髓系细胞触发受体-1。对患者进行随访直至28天，观察死亡率等结局指标。
该研究纳入了82例符合纳入标准的患者。可溶性髓系细胞触发受体-1诊断脓毒症的敏感性为78%，而降钙素原的敏感性为69%。可溶性髓系细胞触发受体-1和降钙素原并行用于脓毒症诊断时，联合敏感性为93%。
降钙素原和可溶性髓系细胞触发受体-1联合使用可提供更高的敏感性，可用于ICU脓毒症筛查。
Roy S, Kothari N, Sharma A, Goyal S, Sankanagoudar S, Bhatia PK, 重症患者中可溶性髓系细胞触发受体-1和降钙素原对脓毒症诊断准确性的比较：一项前瞻性观察性研究。《印度重症医学杂志》2023；27(4):289-293。
